Conference Coverage

Bleeding episodes more common in boys with VWD


 

REPORTING FROM THSNA 2018

– Among children with types 1 and 2 von Willebrand disease (VWD), a higher proportion of boys than girls reported ever having a bleeding episode and using more treatment products. But the trend did not continue among children with type 3 disease.

Those are some of the key findings from a never-before-published analysis of surveillance data from the Centers for Disease Control and Prevention presented by Karon Abe, PhD, during a poster session at the biennial summit of the Thrombosis & Hemostasis Societies of North America.

Dr. Karon Abe is chief of the epidemiology and surveillance branch in the division of blood disorders at the CDC’s National Center on Birth Defects and Developmental Disabilities Doug Brunk/MDedge News

Dr. Karon Abe

Dr. Abe, chief of the epidemiology and surveillance branch in the division of blood disorders at the CDC’s National Center on Birth Defects and Developmental Disabilities, and her associates set out to assess the differences in bleeding characteristics among preadolescent boys and girls by VWD type.

The researchers retrieved data from the UDC (Universal Data Collection System), a federally funded surveillance system of people with hemophilia and other bleeding disorders treated at 130 U.S. Hemophilia Treatment Centers (HTCs) during 1998-2011. Although UDC data collection ended in 2011, a current CDC bleeding surveillance project called Community Counts continues and expands on the work of the UDC.

Between 1998 and 2011, data were collected on 2,413 children with VWD aged 2-12 years. Of these, 2,070 had type 1, 224 had type 2, and 119 had type 3 VWD. The researchers used chi-square analysis and Wilcoxon rank sum tests to assess differences in bleeding characteristics by sex and by type of VWD. Next, they used a multivariate regression model to examine the association between demographic and clinical characteristics and a history of ever having had a bleeding episode among type 1 VWD patients.

Nearly two-thirds of children (65%) were non-Hispanic, 17% were Hispanic, 8% were black, and the remainder were from other ethnicities. In addition, 40% of the children had no family history of a bleeding disorder.

The median age of first bleed was lower among children with type 3 VWD, compared with other VWD types, and was lower among boys than girls with type 1 VWD (36 months vs. 48 months, respectively; P less than .001) and type 3 VWD (9 months vs. 12 months; P = .04), Dr. Abe reported.

Pages

Recommended Reading

FDA advisory committee supports L-glutamine for SCD
MDedge Pediatrics
FDA approves Rebinyn for hemophilia B treatment
MDedge Pediatrics
Prophylactic emicizumab cut bleeds by 87% in hemophilia A with inhibitors
MDedge Pediatrics
Monthly fitusiran showed promise in small phase I hemophilia trial
MDedge Pediatrics
Vaccination does not eliminate risk for meningococcal disease in eculizumab recipients
MDedge Pediatrics
Allele-matching in cord blood transplant yields better survival
MDedge Pediatrics
HAVEN 2: Emicizumab represents new standard of care for hemophilia A with inhibitors
MDedge Pediatrics
FDA grants breakthrough therapy designation for severe aplastic anemia drug
MDedge Pediatrics
States strive to curb costs for a crucial – but exorbitant – hemophilia treatment
MDedge Pediatrics
Of ‘miracles’ and money: Why hemophilia drugs are so expensive
MDedge Pediatrics